

1 **Antimicrobial stewardship among Nigerian children: A pilot study of the knowledge,**
2 **attitude, and practices of prescribers at two tertiary healthcare facilities in Bayelsa State.**

3

4 **Ebiowei S.F Orubu¹, Faith O. Robert², Leonard Emuren³, Boboye Ifie-Ombeh^{4,5}**

5

6 1. Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy,
7 Niger Delta University, Bayelsa State, Nigeria.

8 2. Department of Biochemistry, College of Medicine, Niger Delta University, Bayelsa State,
9 Nigeria

10 3. Section for Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Yale
11 School of Medicine, Yale University, New Haven, Connecticut, USA

12 4. Department of Paediatrics, Niger Delta University Teaching Hospital, Bayelsa State,
13 Nigeria

14 5. Bayelsa Specialist Hospital, Bayelsa State, Nigeria

15

16 Correspondence: samuelorubu@lycos.com

17

18 **Keywords: antimicrobial resistance, antimicrobial stewardship, children, Nigeria**

19

20

21

22

23

24

25 **Running Head: Knowledge attitude practice on antimicrobial stewardship children Nigeria**

26

27

28

29

30

31 Abstract

32 Antimicrobial stewardship (AMS), the evidence-based use of antimicrobials, is an effective
33 strategy in controlling antimicrobial resistance (AMR) in humans by reducing the irrational use of
34 antimicrobials. Stewardship in children is less studied. This study assessed the knowledge, attitude,
35 and practice of physicians prescribing antibiotics to children in Bayelsa State, Nigeria to identify
36 gaps in AMS and possible solutions. Following ethical approval, a semi-structured questionnaire
37 was distributed among 40 paediatricians and gynaecologists at the two public tertiary healthcare
38 facilities in Bayelsa State – the Niger Delta University Teaching Hospital and the Federal Medical
39 Centre – for self-completion. Responses were expressed as percentages and analyzed using
40 Bloom’s cutoffs. The Capability, Opportunity, Motivation, and Behaviour (COM-B) model was
41 employed to identify gaps for intervention in prescribing behavior with gaps in each component
42 identified by aggregate scores <80%. Perceived approaches to improve prescribing among 14
43 selected options were assessed using 5-point Likert scales and options with scores >90% rated the
44 most acceptable. Questionnaires were administered from August to September 2021. The response
45 rate was 68% (27/40). Participants were paediatricians (81%, 22/27) and gynaecologists (19%,
46 5/27). Antimicrobial Susceptibility Testing (AST) was not performed before antibiotic selection
47 nine times out of 10 (89%, 24/27). In a third (37%, 10/27) of cases, 2-3 antibiotics were prescribed.
48 The top three antibiotics, in rank order, were: cefuroxime or amoxicillin 41% (11/27);
49 ciprofloxacin or amoxicillin 30% (8/27), and azithromycin (33%, 9/27). Aggregate COM-B scores
50 were: capability, 74%; opportunity, 78%; and motivation, 87%. The most acceptable (100%,
51 27/27) options to improving antibiotic prescribing were: availability of resistance data, availability
52 of guidelines, readily accessible microbiological data, and easy access to infectious disease
53 physicians. There are gaps in knowledge of AMR and opportunity for rational prescribing. There
54 is need for antimicrobial resistance data to promote pediatric AMS at the surveyed healthcare
55 facilities.

56
57
58
59
60
61
62
63
64
65
66

67 **Introduction**

68 Antimicrobial resistance (AMR), an inherent and developed ability of microorganisms to
69 withstand treatment with antimicrobial agents (1), is a global public health emergency (2,3). The
70 factors contributing to the emergence and spread of AMR in humans are related to the misuse,
71 underuse, or abuse of antimicrobial agents in humans, animals, agriculture, and the environment
72 (1,4). Antimicrobial stewardship (AMS), **the evidence-based use of antimicrobials**, is an
73 effective strategy in controlling AMR in humans by reducing the excessive use of antimicrobials
74 (5). Overall, 50% of global antibiotic use is inappropriate, calling for urgent antimicrobial
75 stewardship to reduce indiscriminate and excessive use of antibiotics (6).

76 Antimicrobial use in children tends to be higher than in adults, especially in developing countries
77 (7). In most Low- and Middle-Income Countries (LMICs), the high burden of infectious diseases,
78 unrestricted access to antimicrobials, and poor awareness promote the indiscriminate use of
79 antimicrobials and drive AMR (8–12). Emerging research show that the use of substandard and
80 falsified (SF), or poor-quality, antimicrobials can also contribute to AMR (13,14).

81 Nigeria, together with four other LMICs, leads the world in deaths from infectious diseases in
82 young children (<5 years old), mostly from lower respiratory tract infections (pneumonia),
83 diarrhea, malaria, and perinatal and neonatal infections. There is little literature on antimicrobial
84 use and antimicrobial stewardship programs in the paediatric population in Nigeria. There are gaps
85 in antimicrobial stewardship activities, generally for Nigeria and specifically for children. A
86 review of the literature on AMS in Nigeria failed to show any studies on AMS in children (15–
87 21).

88 This study aims to understand providers' knowledge, attitude, and practice on antimicrobial use,
89 resistance, and stewardship with the ultimate goal of designing an AMS program for children at
90 the tertiary healthcare level in Nigeria. The objectives were to: (i) assess current antimicrobial
91 prescribing behaviour; and (ii) identify acceptable options for improving rational antimicrobial
92 prescribing for children in this setting.

93

94 **Method**

95 Study design: Cross-sectional questionnaire survey.

96 Ethics: Ethical approval for the study was obtained from NDUTH (NDUTH/REC/0040/2021).

97 Study location: The study location was Bayelsa State, one of the 37 federating units of 36 states
98 and the Federal Capital Territory in Nigeria (Figure 1). It was conveniently selected.

99 Study setting: The study settings were the two public tertiary-level healthcare facilities in Bayelsa
100 State: the Niger Delta University Teaching Hospital (NDUTH), Okolobiri, the primary study
101 location, and the Federal Medical Centre (FMC), Yenagoa. The NDUTH is the teaching hospital
102 of the Niger Delta University. It is a 200-bed hospital providing comprehensive general and
103 specialist healthcare for adults and children (22). Its paediatric department has 25 beds and 30
104 paediatricians. The FMC is a 425-bed hospital with a paediatrician staff strength of 50.

105 Sample size: A sample size of 20 pediatricians was targeted, generally considered appropriate for
106 a pilot study (23,24). To provide information on prescribing practices around pregnancy and
107 childbirth, the survey was extended to prescribers with obstetrics and gynaecology (O&G)
108 specialization, increasing the sample size to 40.

109 Participants: Participants were purposively selected as pediatricians and obstetrics and gynecology
110 specialists.

111 Study instrument: The survey instrument was a semi-structured questionnaire adapted from
112 previously used and validated questionnaire surveys assessing knowledge, attitude, and practice
113 of prescribers and other health workers in Europe (25,26) and Yemen (27). The questionnaire was
114 arranged in 3 “sections” and contained 40 items, not counting an initial consent question and asking
115 any additional question at the end (Supplement Table 1). The questions were adaptive, such that
116 participants did not have to answer all but answered related questions based on their selection of a
117 previous option. Selected questions were repeated to check for individual response reliability.
118 Section I collected demographic data on the prescriber’s specialty and years of experience (2
119 questions). Section II assessed knowledge, attitude and practice, or prescribers’ behaviour. It
120 contained 37 questions on current antibiotic prescription patterns and decision-making, knowledge
121 of, and attitude or perceptions, about both AMR and existing antimicrobial stewardship structures.
122 Knowledge was both real (assessed by 1 question containing 7 “key” statements with true or false
123 answers) and assumed, or perceived, (assessed by 3 questions with Yes/No answers or 5-point
124 Likert scales). Section III consisted of one question that further evaluated perceptions among 14
125 options for improving antibiotic prescribing, or AMS. The questionnaire was made available in
126 both paper and electronic forms. The online questionnaire was prefaced by an introductory section
127 that presented the title, aims, and objectives of the study in an information section and consent,
128 while the paper form included separate information and consent form sections. To ensure
129 completeness in filling the online questionnaire, responses to the main questionnaires were made
130 necessary for submission.

131 Questionnaire administration: Questionnaires were distributed for self-administration in August
132 2021. One researcher (BIO) distributed the paper questionnaire during a departmental meeting at
133 NDUTH and shared the online link via social media (WhatsApp) informally through her
134 professional network. Only participants who consented completed the study. All responses were
135 de-identified.

136 Analysis

137 Analysis was performed using descriptive statistics expressed in proportions or percentages.
138 Questionnaires completed by hand were converted to digital forms for data analysis. Dummy
139 variables were created for questions not completely filled in the paper forms. These were usually
140 “false”, “unsure”, or assigned a “neutral” score. This applied to 5 questions in 2 otherwise
141 completely filled paper questionnaires.

142 To characterize providers’ prescribing behaviour and identify gaps for interventions, the
143 Capability, Opportunity, and Motivation for behavioural change, COM-B, model (26) was utilized
144 (Supplement Table 2). Capability was an umbrella term encompassing individual knowledge,

145 awareness, and perceptions. Opportunity was defined both as factors that lie outside the individual,
146 including awareness or perception of existing facility-level AMS structures, as well as attitudes
147 including confidence in prescribing. Motivation was all the brain processes that energize and direct
148 behaviour and included a self-belief of a key role in the containment of AMR and association
149 between prescribing and the emergence of AMR. All responses on a 5-point Likert scale were re-
150 coded such that “strongly agree” and “agree” were assessed as “agree”, and “strongly disagree”,
151 “neither agree nor disagree”, and “disagree” re-coded as “disagree”. Incomplete responses on
152 paper were assigned the ‘neutral’ “neither agree nor disagree”. Bloom’s cutoffs were then applied
153 to aggregate scores for the relevant responses to identify gaps to target for each behaviour
154 component. With responses assessing participants’ knowledge and awareness of AMR, as well as
155 opportunity for AMS, the cutoffs and interpretations were set at: >80% as “**good**”, 60-79% as
156 “**moderate**”, and <60% as “**poor**” (28). For attitude, these cutoffs were, respectively, analyzed as
157 “**positive**”, “**neutral**”, and “**negative**” (28). Motivation was assessed as “high” (>80%) or “low”
158 (≤80%). **Gaps were scores <80% in any one domain.**

159 To assess acceptable options for improving AMS, responses were re-coded and rated based on
160 percentages. Responses on the 5-point Likert scale were aggregated with very helpful and helpful
161 classified as “helpful” and neutral, unhelpful and very unhelpful re-coded as “unhelpful”. The
162 options recategorized as helpful were then rated as “most acceptable” if they had aggregated scores
163 >90%, “acceptable” with scores of >80-90%, and “maybe **acceptable**” if rated as helpful by 70-
164 80% of respondents.

165 **Results**

166 Responses are detailed in Supplement Table 3.

167 **I. Demographics**

168 Response rate: The questionnaire was distributed to 40 prescribers, out of which 28 responded and
169 completed the questionnaire, giving a participation, and response, rate of 70%. The response from
170 one participant who did not belong to the two target specialties was excluded giving an actual, or
171 adjusted, response rate of 68% (27/40).

172 Participants: Participants were paediatricians 81% (22/27) and gynaecologists 19% (5/27). The
173 majority (85%, 23/27) had more than 5 years experience (37% with 6-10 years; 26% with 11-15
174 years; and 22% with >15 years’ experience) with only 15% (4/27) having less than 5 years
175 experience. The majority (78%, 21/27) saw less than 25 patients a day, most of whom were
176 children under 12 years old (Supplement Table 3a).

177 **II. Antibiotic prescribing practice/behaviour**

178 Decision making: All participants (100%, 27/27) had prescribed an antibiotic within the three
179 months preceding the survey. The primary considerations for prescribing antibiotics were the
180 clinical severity of the case and symptoms the patient presented with (82%, 22/27, respectively).
181 None rated patient demand as a reason for prescribing. A slight majority of prescribers (56%,
182 15/27) felt pressure to prescribe antibiotics. The main reasons for this pressure were the condition
183 of the patient (100%, 15/15) and the fear of complications (93%, 14/15). Forty percent (6/15),

184 agreed or strongly agreed that patient (caregiver/parent) demand was a reason for this pressure
185 (Supplement Table 3b).

186 Pattern: The top three antibiotics usually prescribed were: amoxicillin (including amoxicillin-
187 clavulanate) or cefuroxime which was the first choice of 41% (11/27), ciprofloxacin or amoxicillin
188 (including amoxicillin-clavulanate) as the second choice by 30% (8/27), and azithromycin as the
189 third choice (33%, 9/27). In slightly more than a third (37%, 10/27) of cases 2-3 antibiotics were
190 prescribed.

191 Antibiotic classes most frequently used for Respiratory Tract Infections were penicillins 82%
192 (22/27) and macrolides 78% (21/27). Fluoroquinolones were more frequently used for both
193 Urinary Tract Infections and Gastrointestinal tract (GIT) diseases (63%, 17/27, and 66%, 18/27,
194 respectively). Cephalosporins (56%, 15/27) and penicillins (44%, 12/27) were preferred for skin
195 and soft tissue infections (Supplement Table 3c).

196 Seventy-four percent (20/27) prescribed generic medications, with the remaining 26% (7/27)
197 prescribing by brand names. Quality was the main reason for prescribing by brand (100%, 7/7).

198 Guidelines: Standard Treatment Guidelines, or a guide specific to prescribing, was used by slightly
199 more than half (55%, 15/27) of participants to guide antibiotic prescribing in their facility.

200 AST: Antimicrobial Susceptibility Testing (AST), the use of microbial culture and sensitivity tests,
201 were not performed before antibiotic selection nine times out of 10 (89%, 24/27). This was even
202 the case when there was the possibility (67%, 18/27) of performing AST on-site (100%, 18/18).
203 The most common barriers to AST were time pressure (79%, 19/24) and/or availability of reagents
204 or materials (50%, 12/24).

205 Treatment failure rates: Treatment failure in patients within a month was perceived by the majority
206 (96%, 26/27) of respondents as ranging from <10% (by 52%, 14/27) to between 26-50% (by 11%,
207 3/27).

208 **III. Capability, Opportunity and Motivation for Behaviour Change**

209 AMR capacity: The knowledge and ability to inform others about AMR and use this to guide
210 appropriate prescribing ranged from 70% (moderate) to 89% (good) (Table 1). Overall, AMR
211 capacity was good (81%).

212 Knowledge: There were individual variations in answering the 7 “key” knowledge statements.
213 Only two of these were correctly answered by all 27 (100%). To varying degrees, the answers to
214 the other 5 on knowledge of decreased efficacy of antibiotics with unnecessary use, potential side
215 effects, increased potential of AMR, transmissibility between people, and carriage of AMR in
216 healthy individuals had correct answers ranging from 70-96%. The two most incorrectly answered
217 questions were: “Healthy people can carry antibiotic-resistant bacteria” (70% [19/27], yes) and
218 “Every person treated with antibiotics is at an increased risk of antibiotic-resistant infections”
219 (74% [20/27], yes) (Table 2). Aggregate real knowledge was good.

220 One Health: Knowledge of One Health contributors to AMR varied widely. Only 37%, 11/27
221 correctly agreed that environmental factors such as wastewater contributes to AMR. In contrast,

222 70%, 19/27) correctly agreed that the excessive use of antibiotics in livestock and food production
223 contributes to AMR (Table 3). The aggregate One Health knowledge score was poor.

224 Awareness of WHO AWaRE classification: There was poor awareness of the WHO Access,
225 Watch, and Reserve (AWaRe) classification of antibiotics. Only 15% (4/27) had heard about the
226 classification.

227 Perception of AMR prevalence: All (100%, 27/27) believed AMR to be a problem in Nigeria.
228 However, only 59% (16/27) thought this to be a problem in their health facility; 33% (9/27) were
229 unsure, while 7% (2/27) did not believe AMR to be a problem at their health facility.

230 Perceptions for tackling AMR: Out of four options for tackling AMR in the society, increasing
231 awareness among patients, enforcing prescription laws, and increased testing for antibiotic
232 susceptibility were jointly the most rated solutions by 96% (26/27), followed by improved training
233 for doctors and pharmacists, 93% (25/27).

234 Infection Prevention and Control (Hand hygiene): There was a positive attitude to hand hygiene
235 with all (100%, 27/27) affirming the need to perform hand hygiene if they have used gloves in
236 contact with patients or biological material. In contrast, awareness was of the WHO guidance on
237 hand hygiene was moderate. Three-quarters (74%, 20/27) could list the WHO's five moments of
238 hand hygiene, while the rest were either unsure (22%, 6/27) or could not (4%, 1/27).

239 Opportunity: The overall score for opportunity was 78%. The majority (85%, 23/27) had easy
240 access to guidelines for managing infections and were confident making antibiotic prescription
241 decisions (81%, 23/27) but did not feel supported to not prescribe antibiotics when not needed,
242 63% (17/27) (Table 4).

243 The majority reported the presence of a Drug and Therapeutics Committee (74%, 20/27) and a
244 Hospital Formulary or Essential Medicines List (82%, 22/27).

245 Motivation: The motivation score among participants was 87% overall. Most agreed that there is
246 a connection between their antibiotics prescription pattern and the emergence and spread of AMR
247 in patients (78%, 21/27) and that they have a crucial role in helping to control AMR, 96% (26/27)
248 (Table 5).

249 IV. Perceived options to improve antibiotic prescribing: The top measures to improve antibiotic
250 prescribing were: availability of local/national resistance data, availability of local/national
251 guidelines/policies/protocols, readily accessible microbiological data, and easy access to
252 infectious disease physicians (100%, 27/27, each); regular audits and feedback on antibiotic
253 prescribing (96%, 26/27); and educational sessions on prescribing (93%, 25/27). The least rated
254 measures to improve prescribing were computer-aided prescribing (44%, 12/27), restriction of
255 prescription of all antibiotics (30%, 8/27), and speaking to a pharmaceutical representative (15%,
256 4/27) (Table 6).

257 **Discussion**

258 Targeted or evidence-based antibiotic prescribing in children is an urgent clinical need. This is
259 because the indiscriminate or wrong use of antibiotics in children may not only facilitate the

260 emergence and spread of AMR but can also lead to other diseases later in life (29). It is thought
261 that intestinal dysbiosis resulting from early antibiotic exposures predisposes to paediatric
262 idiopathic arthritis, inflammatory bowel disease, asthma, and diabetes(citation).

263 This study attempted to evaluate the knowledge, attitude, and practices on antimicrobial use,
264 resistance, and stewardship, as well as attitude towards interventions to strengthen AMS among
265 physicians who prescribe antibiotics to children and pregnant women at two tertiary healthcare
266 facilities in Nigeria. While there are studies on antimicrobial utilization in the study location, this
267 only addressed structural gaps and did not focus on children (30).

268 Empirical prescribing, making antibiotic choices based on experience and not on AST, is the
269 predominant mode of prescribing in this setting, similar to findings previously reported (30). While
270 efforts to change this practice towards more evidence-based prescribing are established or
271 expanding in many countries in the northern hemisphere (31,32), uptake in the southern
272 hemisphere is low. In Nigeria, one study found that none out of 12 surveyed tertiary hospitals had
273 a formal AMS structure (33).

274 Prescribing is a complex, time-dependent activity in which the prescriber will consider, amongst
275 other things, the symptoms and severity at presentation, the age, allergy history, drug-drug
276 interaction, previous resistant pattern if known, and cost and family dynamics. In almost all cases,
277 the symptoms and severity dictate treatment choice, as is the situation in this study. Without
278 exception, participants in this study recognized the need for resistance data and an antibiotic
279 prescribing guide.

280 Overall, the antibiotic prescribing pattern in this study agrees with the use pattern across Bayelsa
281 State from a recent prescription audit (30). The most prescribed antibiotics in this study were
282 cefuroxime (a cephalosporin with antistaphylococcal effect), amoxicillin including amoxicillin-
283 clavulanic acid (penicillin), ciprofloxacin (a fluoroquinolone), and azithromycin (a macrolide).
284 These were also the most frequently prescribed in the audit, except for azithromycin. A 20-year
285 literature review of irrational prescribing also found penicillins, fluoroquinolones, and
286 cephalosporins to be the most prescribed antibiotics worldwide (34).

287 Most of the commonly prescribed antibiotics (azithromycin, cefuroxime, and ciprofloxacin) were
288 in the WHO Watch category - a group of antibiotics of different therapeutic classes that should be
289 prioritized because of their more significant risk of selecting for AMR. One reason for using the
290 AWaRe classification is to ensure that 60% of prescribing is from the access group of antibiotics.
291 The findings from the prescription audit earlier (30) showed that this is not yet the case in this
292 setting. Indeed, most of the prescribers included in this survey had not heard of this categorization
293 intended to improve antibiotic use and reduce AMR (6,35).

294 Lack of access to rapid pathogen detection and antimicrobial susceptibility testing remains a
295 barrier to AMS. Rapid diagnostic tests (RDTs) can reduce the time interval to use AST for guiding
296 prescribing (36). RDTs using molecular techniques are now commercially available for the
297 identification of various microbial etiological agents, including syphilis (37), invasive
298 *Streptococcus pyogenes* (38), and helpful in differentiating bacterial from viral causes of
299 respiratory diseases (39). This innovation has also led to several approved devices that can rapidly

300 assess (<1-24hrs) the antimicrobial identification and sensitivity when there is infection (40,41).
301 However, RDTs may not be readily available in resource-constrained settings like ours.

302 Approaches to tackle AMR in tertiary healthcare facilities should start from the community. The
303 lack of suitable formulations for children potentially complicates antimicrobial use. One study of
304 the WHO Essential Medicines List used to inform the selection, and use of medicines for children
305 found that over 70% of the recommended medicines for oral use in the 2011-2019 lists were not
306 suitable for use in children less than 5 years old (42). This situation leads to the extemporaneous
307 preparation or compounding of medicines for children with potential safety and efficacy issues.
308 Although inpatient antibiotic use is usually via the parenteral route for younger children (43,44),
309 the easy over-the-counter (OTC) access to oral antibiotics at the community level can complicate
310 efforts aimed at AMS. It is, therefore, important to address AMR through community-targeted
311 programs in order to reduce the burden placed on tertiary healthcare facilities. A recent study
312 suggests that reconstituted amoxicillin-clavulanic acid suspension stored under room temperature
313 these settings undergoes rapid quality changes over 7 days (45), making addressing paediatric
314 AMS challenging.

315 This study clearly shows that there is a need to improve providers' knowledge on AMR and AMS.
316 Providers also need to be better acquainted with the WHO guidelines among pediatricians and
317 other practitioners who prescribe antibiotics for use in the pediatric population. Continuing
318 medical education for the rational use of antibiotics at regular intervals could motivate the
319 necessary behaviour change among pediatric practitioners. This study is not without its limitations.
320 For one, we did not assess the impact of cost on prescribing behavior, nor did it evaluate
321 practitioners' knowledge of the pharmacodynamics and pharmacokinetics of antibiotics prescribed,
322 as this was beyond the scope of the current research effort.

323

324

325 **Conclusion**

326 This study evaluated the knowledge, attitude, and practices of providers who prescribe antibiotics
327 to children at two tertiary healthcare facilities in Bayelsa State, Nigeria, with the goal of
328 understanding barriers and facilitators for establishing an antimicrobial stewardship program for
329 children.

330 There is a need for readily accessible resistance data and information to guide rational
331 antimicrobial prescribing in tertiary healthcare settings in the Niger Delta region of Nigeria. A
332 clinical decision support system that integrates local resistance data to guide antibiotic prescribing
333 would be an effective pediatric AMS strategy in this and similar settings. To be effective, this
334 system should be readily accessible to prescribers and regularly updated with resistance data.
335 Shared ownership, fostered through a participatory approach, could help enhance uptake and use.
336 Rapid diagnostic tests to rapidly inform antibiotic choice are a must and would facilitate
337 transitioning from empiric therapy to definitive therapy. Future research should focus on

338 improving AMS at the institutional and national levels through the systematic collection and use
339 of AMR data.

340

341

342 **Financial support**

343 We confirm no financial support was received for this project.

344

345 **Disclosures regarding real or perceived conflicts of interest.**

346 None to declare.

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367 **References**

- 368 1. Antimicrobial resistance | EFSA [Internet]. [cited 2021 Oct 29]. Available from:
369 <https://www.efsa.europa.eu/en/topics/topic/antimicrobial-resistance>
- 370 2. Toner E, Adalja A, Gronvall GK, Cicero A, Inglesby TV. Antimicrobial resistance is a
371 global health emergency. *Health Secur.* 2015;13(3):153–5.
- 372 3. WHO. Global Action Plan on Antimicrobial Resistance [Internet]. 2015 [cited 2019 Dec
373 25]. Available from:
374 [https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence](https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1)
375 [=1](https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1)
- 376 4. Shallcross LJ, Davies DSC. Antibiotic overuse: a key driver of antimicrobial resistance. *Br*
377 *J Gen Pract.* 2014 Dec;64(629):604–5.
- 378 5. Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of
379 hospital antimicrobial stewardship programs [ASPs]: a systematic review. *Antimicrob*
380 *Resist Infect Control.* 2019 Feb 12;8(1):35.
- 381 6. WHO. AWaRe Policy Brief [Internet]. 2019 [cited 2020 Nov 15]. Available from:
382 https://adoptaware.org/assets/pdf/aware_policy_brief.pdf
- 383 7. Allwell-Brown G, Hussain-Alkhateeb L, Kitutu FE, Strömdahl S, Mårtensson A, Johansson
384 EW. Trends in reported antibiotic use among children under 5 years of age with fever,
385 diarrhoea, or cough with fast or difficult breathing across low-income and middle-income
386 countries in 2005–17: a systematic analysis of 132 national surveys from 73 countries.
387 *Lancet Glob Health.* 2020 Jun 1;8(6):e799–807.
- 388 8. Ramay BM, Caudell MA, Córdón-Rosales C, Archila LD, Palmer GH, Jarquin C, et al.
389 Antibiotic use and hygiene interact to influence the distribution of antimicrobial-resistant
390 bacteria in low-income communities in Guatemala. *Sci Rep.* 2020 Aug 13;10(1):13767.
- 391 9. WHO. Antimicrobial resistance [Internet]. 2020 [cited 2020 Nov 17]. Available from:
392 <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
- 393 10. Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in
394 developing countries: causes and control strategies. *Antimicrob Resist Infect Control.* 2017
395 Dec;6(1):47.
- 396 11. Iskandar K, Molinier L, Hallit S, Sartelli M, Catena F, Coccolini F, et al. Drivers of
397 Antibiotic Resistance Transmission in Low- and Middle-Income Countries from a “One
398 Health” Perspective—A Review. *Antibiotics.* 2020 Jul;9(7):372.
- 399 12. Pokharel S, Raut S, Adhikari B. Tackling antimicrobial resistance in low-income and
400 middle-income countries. *BMJ Glob Health.* 2019 Nov 1;4(6):e002104.

- 401 13. Weinstein ZB, Zaman MH. Evolution of Rifampin Resistance in *Escherichia coli* and
402 *Mycobacterium smegmatis* Due to Substandard Drugs. *Antimicrob Agents Chemother*.
403 2019 Jan 1;63(1):e01243-18.
- 404 14. Nwokike J, Clark A, Nguyen PP. Medicines quality assurance to fight antimicrobial
405 resistance. *Bull World Health Organ*. 2018 Feb 1;96(2):135–7.
- 406 15. Jewoola OO, Bode-Sojobi IO, Ogunsola FT, Okonji PE. High carriage rates of extended-
407 spectrum beta-lactamase-producing enterobacteriaceae in children at admission into
408 paediatric wards of a university teaching hospital in Lagos, Nigeria. *Niger Postgrad Med J*.
409 2020 Jun;27(2):136–42.
- 410 16. Ughasoro MD, Nwakoby IC, Onwujekwe OE, Odike AI. Drug pooling: A cost-saving
411 strategy to enhance antibiotics availability for pediatric inpatient in Nigeria. *Niger J Clin
412 Pract*. 2019 Feb;22(2):232–7.
- 413 17. Omolajaiye SA, Afolabi KO, Iweriebor BC. Pathotyping and Antibiotic Resistance
414 Profiling of *Escherichia coli* Isolates from Children with Acute Diarrhea in Amatole
415 District Municipality of Eastern Cape, South Africa. *BioMed Res Int*. 2020;2020:4250165.
- 416 18. Roberts AA, Fajolu I, Oshun P, Osuagwu C, Awofeso O, Temiye E, et al. Feasibility study
417 of prospective audit, intervention and feedback as an antimicrobial stewardship strategy at
418 the Lagos University Teaching Hospital. *Niger Postgrad Med J*. 2020 Mar;27(1):54–8.
- 419 19. Raji MA, Jamal W, Ojemhen O, Rotimi VO. Point-surveillance of antibiotic resistance in
420 Enterobacteriaceae isolates from patients in a Lagos Teaching Hospital, Nigeria. *J Infect
421 Public Health*. 2013 Dec;6(6):431–7.
- 422 20. Tebano G, Li G, Beovic B, Bielicki J, Brink A, Enani MA, et al. Essential and forgotten
423 antibiotics: An inventory in low- and middle-income countries. *Int J Antimicrob Agents*.
424 2019 Sep;54(3):273–82.
- 425 21. Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, et al. Strategies to
426 Improve Antimicrobial Utilization with a Special Focus on Developing Countries. *Life
427 Basel Switz*. 2021 Jun 7;11(6):528.
- 428 22. Ogoina D, Izibewule JH, Ogunleye A, Ederiane E, Anebonam U, Neni A, et al. The 2017
429 human monkeypox outbreak in Nigeria—Report of outbreak experience and response in the
430 Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. *PLOS ONE*. 2019 Apr
431 17;14(4):e0214229.
- 432 23. Zetts RM, Garcia AM, Doctor JN, Gerber JS, Linder JA, Hyun DY. Primary Care
433 Physicians’ Attitudes and Perceptions Towards Antibiotic Resistance and Antibiotic
434 Stewardship: A National Survey. *Open Forum Infect Dis*. 2020 Jul 1;7(7):ofaa244.
- 435 24. Spervasilis N, Ierodiakonou D, Milioni A, Markaki L, Kofteridis DP, Tsioutis C.
436 Assessing the knowledge, attitudes and perceptions of junior doctors on antimicrobial use
437 and antimicrobial resistance in Greece. *J Glob Antimicrob Resist*. 2020 Jun 1;21:296–302.

- 438 25. World Health Organization. WHO methodology for point prevalence survey on antibiotic
439 use in hospitals [Internet]. Geneva; 2018 [cited 2020 Jul 15]. Available from:
440 [https://apps.who.int/iris/bitstream/handle/10665/280063/WHO-EMP-IAU-2018.01-](https://apps.who.int/iris/bitstream/handle/10665/280063/WHO-EMP-IAU-2018.01-eng.pdf?ua=1)
441 [eng.pdf?ua=1](https://apps.who.int/iris/bitstream/handle/10665/280063/WHO-EMP-IAU-2018.01-eng.pdf?ua=1)
- 442 26. Hertzog MA. Considerations in determining sample size for pilot studies. *Res Nurs Health*.
443 2008 Apr;31(2):180–91.
- 444 27. Viechtbauer W, Smits L, Kotz D, Budé L, Spigt M, Serroyen J, et al. A simple formula for
445 the calculation of sample size in pilot studies. *J Clin Epidemiol*. 2015 Nov;68(11):1375–9.
- 446 28. Gerber JS, Jackson MA, Tamma PD, Zaoutis TE, Committee on Infectious Diseases PIDS.
447 Antibiotic Stewardship in Pediatrics. *Pediatrics* [Internet]. 2021 Jan 1 [cited 2021 Oct
448 29];147(1). Available from:
449 <https://pediatrics.aappublications.org/content/147/1/e2020040295>
- 450 29. Kpokiri EE, Taylor DG, Smith FJ. Development of Antimicrobial Stewardship Programmes
451 in Low and Middle-Income Countries: A Mixed-Methods Study in Nigerian Hospitals.
452 *Antibiotics*. 2020 Apr;9(4):204.
- 453 30. McGregor JC, Fitzpatrick MA, Suda KJ. Expanding Antimicrobial Stewardship Through
454 Quality Improvement. *JAMA Netw Open*. 2021 Feb 26;4(2):e211072.
- 455 31. Kronman MP, Banerjee R, Duchon J, Gerber JS, Green MD, Hersh AL, et al. Expanding
456 Existing Antimicrobial Stewardship Programs in Pediatrics: What Comes Next. *J Pediatr*
457 *Infect Dis Soc*. 2018 Aug 17;7(3):241–8.
- 458 32. Ogoina D, Iliyasu G, Kwaghe V, Otu A, Akase IE, Adekanmbi O, et al. Predictors of
459 antibiotic prescriptions: a knowledge, attitude and practice survey among physicians in
460 tertiary hospitals in Nigeria. *Antimicrob Resist Infect Control*. 2021 Dec;10(1):73.
- 461 33. Sweileh WM. Global research publications on irrational use of antimicrobials: call for more
462 research to contain antimicrobial resistance. *Glob Health*. 2021 Dec;17(1):1–12.
- 463 34. Brink AJ, Mendelson M. Be AWaRe: new metrics for paediatric antibiotic stewardship.
464 *Lancet Infect Dis*. 2019 Jan;19(1):6–7.
- 465 35. Beganovic M, McCreary EK, Mahoney MV, Dionne B, Green DA, Timbrook TT. Interplay
466 between Rapid Diagnostic Tests and Antimicrobial Stewardship Programs among Patients
467 with Bloodstream and Other Severe Infections. *J Appl Lab Med*. 2019 Jan 1;3(4):601–16.
- 468 36. Phang Romero Casas C, Martyn-St James M, Hamilton J, Marinho DS, Castro R, Harnan S.
469 Rapid diagnostic test for antenatal syphilis screening in low-income and middle-income
470 countries: a systematic review and meta-analysis. *BMJ Open*. 2018 Feb;8(2):e018132.
- 471 37. Reijtman V, García ME, Mastroianni A, Isasmendi A, Pinheiro JL, Pérez G, et al.
472 Evaluation of a rapid diagnostic test for the detection of *Streptococcus pyogenes* in invasive
473 infections. *Rev Argent Microbiol*. 2020 Dec;52(4):261–5.

- 474 38. Shirley M. FebriDx®: A Rapid Diagnostic Test for Differentiating Bacterial and Viral
475 Aetiologies in Acute Respiratory Infections. *Mol Diagn Ther.* 2019 Dec;23(6):803–9.
- 476 39. Maugeri G, Lychko I, Sobral R, Roque ACA. Identification and Antibiotic-Susceptibility
477 Profiling of Infectious Bacterial Agents: A Review of Current and Future Trends.
478 *Biotechnol J.* 2019 Jan;14(1):1700750.
- 479 40. Gonzalez MD, McElvania E. New Developments in Rapid Diagnostic Testing for Children.
480 *Infect Dis Clin North Am.* 2018 Mar;32(1):19–34.
- 481 41. Orubu ESF, Duncan J, Tuleu C, Turner MA, Nunn A. WHO essential medicines for
482 children 2011–2019: age-appropriateness of enteral formulations. *Arch Dis Child.* 2021 Sep
483 3;archdischild-2021-321831.
- 484 42. Versporten A, Bielicki J, Drapier N, Sharland M, Goossens H. The Worldwide Antibiotic
485 Resistance and Prescribing in European Children (ARPEC) point prevalence survey:
486 developing hospital-quality indicators of antibiotic prescribing for children. *J Antimicrob
487 Chemother.* 2016 Apr;71(4):1106–17.
- 488 43. Hsia Y, Sharland M, Jackson C, Wong ICK, Magrini N, Bielicki JA. Consumption of oral
489 antibiotic formulations for young children according to the WHO Access, Watch, Reserve
490 (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-
491 income countries. *Lancet Infect Dis.* 2019 Jan 1;19(1):67–75.
- 492 44. Mack I, Sharland M, Brussee JM, Rehm S, Rentsch K, Bielicki J. Insufficient Stability of
493 Clavulanic Acid in Widely Used Child-Appropriate Formulations. *Antibiotics.* 2021
494 Feb;10(2):225.
- 495
- 496
- 497
- 498



Figure 1 Map of Nigeria with study location indicated by the rectangle.

[Source:

https://en.wikipedia.org/wiki/File:Map_of_Nigerian_States_with_names.png#/media/File:Map_of_Nigerian_States_with_names.png

Table 1: Knowledge of AMR and the ability to inform others and to use this to guide prescribing ranked by the re-coded “agree”

		Strongly Disagree	Disagree	Neither disagree nor agree	Agree	Strongly agree	"Agree"
a	I know what antibiotic resistance is	3			6	18	89%
b	I know what information to give to individuals about prudent use of antibiotics and antibiotic resistance	3		1	5	18	85%
c	I know sufficient knowledge about how to use antibiotics appropriately for my current practice	2	3	3	7	12	70%
Aggregate score							81%

Table 2: Knowledge about the dynamics of AMR emergence and spread rated by the overall proportion of correct answers

		TRUE	FALSE	Correct answer	Correct (%)
a	Antibiotics are effective against viruses		27	FALSE	100%
b	Antibiotics are effective against cold and flu		27	FALSE	100%
c	Taking antibiotics has associated side effects such as diarrhea, colitis, or allergy	26	1	TRUE	96%
d	Unnecessary use of antibiotics makes them become ineffective	25	2	TRUE	93%
e	Antibiotic resistant bacteria can spread from person to person	22	5	TRUE	81%
f	Every person treated with antibiotics is at an increased risk of antibiotic resistant infection	20	7	TRUE	74%
g	Healthy people can carry antibiotic resistant bacteria	19	8	TRUE	70%
Aggregate score					88%

Table 3 Knowledge about One Health components of AMR

		Strongly Disagree	Disagree	Neither disagree nor agree	Agree	Strongly agree	"Correct"
a	Environmental factors such as waste water in the environment	2	3	12	7	3	37%
b	Excessive use of antibiotics in livestock and food production	1	1	7	14	4	67%
Aggregate score							52%

Table 4 Opportunity for rational (evidence-based) antimicrobial prescribing

		Strongly Disagree	Disagree	Neither disagree nor agree	Agree	Strongly agree	Total	Agree
a	I consider antibiotic resistance when treating a patient			2	14	11	27	93%
b	I have easy access to guidelines I need on managing infections	2		2	21	2	27	85%
c	I am confident making antibiotic prescribing decisions	1		4	12	10	27	81%
d	I have easy access to the materials I need to give advice on prudent antibiotic use and antibiotic resistance	4		2	19	2	27	78%
e	I have good opportunities to provide advice on prudent use to individuals (patients/public)	2		4	16	5	27	78%
f	I have confidence in the antibiotic guidelines available to me	1		8	17	1	27	67%
g	I feel supported to not prescribe antibiotics when they are not necessary	5		5	9	8	27	63%
Aggregate score								78%

Table 5 Motivation to improving prescribing by the re-coded variable "agree"

		Strongly Disagree	Disagree	Neither disagree nor agree	Agree	Strongly agree	Agree
a	There is a connection between my prescribing of antibiotics and emergence and spread of antibiotic resistant bacteria		1	5	8	13	78%
b	I have a key role in helping control antibiotic resistance			1	5	21	96%
	Aggregate score						87%

Note: Aggregate score is the overall average score of participants across questions.

Table 6: Perceived options among 27 surveyed participants for improving antibiotic prescribing ranked from high to low using the re-coded variable “helpful”

No.	Options	Responses (no. of participants)					Helpful	
		Very helpful	Helpful	Neutral	Unhelpful	Very helpful		Total responses
1	Availability of local / national guidelines / policies / protocols	18	9				27	100%
2	Availability of local/national resistance data	20	7				27	100%
3	Readily accessible microbiological advice	13	14				27	100%
4	Readily accessible advice from Infectious Disease physician	18	9				27	100%
5	Regular audit and feedback on antibiotic prescribing in your facility	10	16	1			27	96%
6	Educational sessions on prescribing	15	10	2			27	93%
7	Advice from senior colleagues	5	19	3			27	89%
8	Restriction of prescription of certain antibiotics	11	13	3			27	89%
9	Readily accessible advice from infection control team	10	11	6			27	78%
10	Presence of an antimicrobial management team	9	10	8			27	70%
11	Readily accessible advice from a pharmacist	6	13	8			27	70%
12	Computer-aided prescribing	7	5	12	3		27	44%
13	Restriction of prescription of all antibiotics	2	6	9	7	3	27	30%
14	Speaking to a pharmaceutical representative	2	2	16	6	1	27	15%

